196 related articles for article (PubMed ID: 27097949)
1. The IL33/ST2 axis in Sjogren syndrome in relation to disease activity.
Margiotta DP; Navarini L; Vadacca M; Lo Vullo M; Pignataro F; Basta F; Afeltra A
Eur Rev Med Pharmacol Sci; 2016 Apr; 20(7):1295-9. PubMed ID: 27097949
[TBL] [Abstract][Full Text] [Related]
2. The Interleukin 33/ST2 axis in patients with primary Sjögren syndrome: expression in serum and salivary glands, and the clinical association.
Jung SM; Lee J; Baek SY; Lee JH; Lee J; Park KS; Park SH; Kim HY; Kwok SK
J Rheumatol; 2015 Feb; 42(2):264-71. PubMed ID: 25512474
[TBL] [Abstract][Full Text] [Related]
3. Potential involvement of the IL-33-ST2 axis in the pathogenesis of primary Sjogren's syndrome.
Awada A; Nicaise C; Ena S; Schandéné L; Rasschaert J; Popescu I; Gangji V; Soyfoo MS
Ann Rheum Dis; 2014 Jun; 73(6):1259-63. PubMed ID: 24385203
[TBL] [Abstract][Full Text] [Related]
4. Potential contribution of interleukin-33 to the development of interstitial lung disease in patients with primary Sjogren's Syndrome.
Zhao L; Yao L; Yuan L; Xia L; Shen H; Lu J
Cytokine; 2013 Oct; 64(1):22-4. PubMed ID: 23910012
[TBL] [Abstract][Full Text] [Related]
5. Increased levels of circulating microparticles in primary Sjögren's syndrome, systemic lupus erythematosus and rheumatoid arthritis and relation with disease activity.
Sellam J; Proulle V; Jüngel A; Ittah M; Miceli Richard C; Gottenberg JE; Toti F; Benessiano J; Gay S; Freyssinet JM; Mariette X
Arthritis Res Ther; 2009; 11(5):R156. PubMed ID: 19832990
[TBL] [Abstract][Full Text] [Related]
6. Impaired degradation and aberrant phagocytosis of necrotic cell debris in the peripheral blood of patients with primary Sjögren's syndrome.
Fragoulis GE; Vakrakou AG; Papadopoulou A; Germenis A; Kanavakis E; Moutsopoulos HM; Manoussakis MN
J Autoimmun; 2015 Jan; 56():12-22. PubMed ID: 25228497
[TBL] [Abstract][Full Text] [Related]
7. Increased soluble ST2 and IL‑4 serum levels are associated with disease severity in patients with membranous nephropathy.
Zhang Z; Liu X; Wang H; Qu Z; Crew R; Zhang N; Jiang Y
Mol Med Rep; 2018 Feb; 17(2):2778-2786. PubMed ID: 29207152
[TBL] [Abstract][Full Text] [Related]
8. Relationships between increased circulating YKL-40, IL-6 and TNF-α levels and phenotypes and disease activity of primary Sjögren's syndrome.
Chen C; Liang Y; Zhang Z; Zhang Z; Yang Z
Int Immunopharmacol; 2020 Nov; 88():106878. PubMed ID: 32791244
[TBL] [Abstract][Full Text] [Related]
9. Autoantibody to MDM2: A potential serological marker of primary Sjogren's syndrome.
Liu Y; Liao X; Wang Y; Chen S; Sun Y; Lin Q; Shi G
Oncotarget; 2017 Feb; 8(9):14306-14313. PubMed ID: 28147328
[TBL] [Abstract][Full Text] [Related]
10. Association of BAFF and IL-17A with subphenotypes of primary Sjögren's syndrome.
Deng F; Chen J; Zheng J; Chen Y; Huang R; Yin J; Gao X; Lin Q; Huang C; Gao Y; Yu X; Liu Z
Int J Rheum Dis; 2016 Jul; 19(7):715-20. PubMed ID: 25941062
[TBL] [Abstract][Full Text] [Related]
11. Impact of the leucocyte immunoglobulin-like receptor A3 (LILRA3) on susceptibility and subphenotypes of systemic lupus erythematosus and Sjögren's syndrome.
Du Y; Su Y; He J; Yang Y; Shi Y; Cui Y; Luo C; Wu X; Liu X; Hu F; Ma X; Zheng L; Zhang J; Zuo X; Sheng Y; Wu L; Zhang X; Guo J; Li Z
Ann Rheum Dis; 2015 Nov; 74(11):2070-5. PubMed ID: 24906639
[TBL] [Abstract][Full Text] [Related]
12. The expression of death decoy receptor 3 was increased in the patients with primary Sjögren's syndrome.
Liu J; Zhao Z; Zou Y; Zhang M; Zhou Y; Li Y; Pang Z; Jin W
Clin Rheumatol; 2015 May; 34(5):879-85. PubMed ID: 25564309
[TBL] [Abstract][Full Text] [Related]
13. CD4 T lymphocyte autophagy is upregulated in the salivary glands of primary Sjögren's syndrome patients and correlates with focus score and disease activity.
Alessandri C; Ciccia F; Priori R; Astorri E; Guggino G; Alessandro R; Rizzo A; Conti F; Minniti A; Barbati C; Vomero M; Pendolino M; Finucci A; Ortona E; Colasanti T; Pierdominici M; Malorni W; Triolo G; Valesini G
Arthritis Res Ther; 2017 Jul; 19(1):178. PubMed ID: 28743286
[TBL] [Abstract][Full Text] [Related]
14. Soluble ST2 is increased in systemic lupus erythematous and is a potential marker of lupus nephritis.
Moreau A; Nicaise C; Awada A; Soyfoo MS
Clin Exp Rheumatol; 2022 May; 40(5):897-903. PubMed ID: 34128798
[TBL] [Abstract][Full Text] [Related]
15. Serum soluble interleukin-2 receptor is a useful biomarker for disease activity but not for differential diagnosis in IgG4-related disease and primary Sjögren's syndrome adults from a defined population.
Akiyama M; Sasaki T; Kaneko Y; Yasuoka H; Suzuki K; Yamaoka K; Takeuchi T
Clin Exp Rheumatol; 2018; 36 Suppl 112(3):157-164. PubMed ID: 29465360
[TBL] [Abstract][Full Text] [Related]
16. Increased CD200 levels in peripheral blood mononuclear cells of patients with primary Sjögren's syndrome.
Liu TT; Zeng XP; Gu ML; Deng AM
Int J Rheum Dis; 2020 May; 23(5):654-660. PubMed ID: 32180363
[TBL] [Abstract][Full Text] [Related]
17. Increased serum levels of IL-33 and soluble ST2 in neonates with human cytomegalovirus infection.
Chen Y; Qian J
J Med Virol; 2018 Aug; 90(8):1383-1388. PubMed ID: 29663450
[TBL] [Abstract][Full Text] [Related]
18. Pathophysiologic role of Interleukin-33/ST2 in Sjögren's syndrome.
Soyfoo MS; Nicaise C
Autoimmun Rev; 2021 Mar; 20(3):102756. PubMed ID: 33476812
[TBL] [Abstract][Full Text] [Related]
19. Brain-derived neurotrophic factor and nerve growth factor correlate with T-cell activation in primary Sjogren's syndrome.
Fauchais AL; Boumediene A; Lalloue F; Gondran G; Loustaud-Ratti V; Vidal E; Jauberteau MO
Scand J Rheumatol; 2009; 38(1):50-7. PubMed ID: 18830907
[TBL] [Abstract][Full Text] [Related]
20. Serum soluble Fas/APO-1 is increased in patients with primary Sjögren's syndrome.
Fujihara T; Takeuchi T; Tsubota K; Kayagaki N; Yagita H; Okumura K; Abe T
Clin Rheumatol; 1998; 17(6):496-9. PubMed ID: 9890678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
